Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2021-04-14 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于向特定对象发行股票申请收到上海证券交易所审核问询函的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the receipt of an inquiry letter from the Shanghai Stock Exchange about the company's application for a private placement of shares. It discusses the review process, the need for regulatory approval, and the company's commitment to disclose further information. The document is short (635 characters) and serves as a regulatory update on the financing process rather than the actual financing report or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP).
2021-04-14 Chinese
神州细胞2020年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled "2020年度财务报表及审计报告" which translates to "2020 Annual Financial Statements and Audit Report." It contains detailed financial statements such as consolidated and company balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. It also includes an audit report issued by a registered accounting firm (PwC Zhongtian) with signatures of certified public accountants. The document discusses audit opinions, key audit matters, management responsibilities, and auditor responsibilities, all typical components of a standalone audit report. The length is substantial (15,000 characters), and the content is the full audit report and financial statements, not merely an announcement or certification. Therefore, this document fits the category of an Audit Report / Information (AR). FY 2020
2021-04-14 Chinese
神州细胞关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding a change in accounting policy related to the adoption of a new lease accounting standard effective January 1, 2021. It details the nature of the accounting policy change, its impact on the company, and the approval process by the board and supervisory committee. The document is relatively short (1942 characters) and does not contain financial statements or detailed financial data. It is an announcement about an accounting policy change rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-04-14 Chinese
神州细胞2020年度募集资金存放与实际使用情况专项报告及鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled '2020年度募集资金存放与实际使用情况专项报告及鉴证报告' which translates to '2020 Annual Report on the Custody and Actual Use of Raised Funds and Verification Report'. It includes an audit report by PwC (普华永道) on the use and management of funds raised by the company in 2020. The content focuses on the verification of the company's compliance with regulatory requirements regarding the management and use of raised funds, including detailed financial figures and audit conclusions. This is a standalone audit/verification report related to the use of capital raised, not a full annual report or earnings release. It is not a mere announcement or certification but contains substantive audit findings and financial data related to the raised funds. Therefore, it fits the category of an Audit Report / Information (AR). FY 2020
2021-04-14 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2020年度募集资金存放与使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2020 annual verification of the deposit and use of raised funds by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes specific financial figures about the amount raised, usage, balance, management, and regulatory compliance related to the raised funds. The document references regulatory guidelines and laws related to the management and use of raised funds, and includes audit opinions and verification reports from accounting firms. The content focuses on the management and use of capital raised through a public offering, including detailed tables and explanations of fund usage, compliance, and supervisory opinions. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report but contains substantive financial and regulatory information about the use of raised funds for the fiscal year 2020. Therefore, the appropriate classification is CAP with high confidence.
2021-04-14 Chinese
神州细胞2020年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2020年度募集资金存放与实际使用情况的专项报告" which translates to "2020 Annual Special Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised through an IPO, the actual use of these funds, the management and storage of the funds, and includes audit and verification opinions from accounting firms and sponsors. The document references regulatory guidelines related to the management and use of raised funds and provides detailed financial figures on the raised capital and its usage. This type of report is a specialized disclosure focused on the use of capital raised by the company, which aligns with the category of Capital/Financing Update (CAP). The document is substantive and not merely an announcement or certification, and it is not a full annual report or interim report. Therefore, the best fitting classification is CAP.
2021-04-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.